デフォルト表紙
市場調査レポート
商品コード
1565173

オリゴヌクレオチド治療薬の世界市場

Oligonucleotide Therapeutics

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
オリゴヌクレオチド治療薬の世界市場
出版日: 2024年10月04日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

オリゴヌクレオチド治療薬の世界市場は2030年までに49億米ドルに到達

2023年に28億米ドルと推定されるオリゴヌクレオチド治療薬の世界市場は、2030年には49億米ドルに達し、分析期間2023-2030年のCAGRは8.7%で成長すると予測されます。本レポートで分析したセグメントの1つであるアンチセンス/RNAIオリゴヌクレオチド技術は、CAGR 9.3%を記録し、分析期間終了までに40億米ドルに達すると予測されます。その他の技術分野の成長率は、分析期間中CAGR 6.4%と推定されます。

米国市場は7億6,260万米ドルと推定、中国はCAGR 7.9％で成長予測

米国のオリゴヌクレオチド治療薬市場は、2023年に7億6,260万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGRを7.9%として、2030年までに7億4,490万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.2%と6.9%と予測されています。欧州では、ドイツがCAGR約6.9%で成長すると予測されています。

世界のオリゴヌクレオチド治療薬市場- 主要動向と促進要因のまとめ

オリゴヌクレオチド治療薬とは何か？

オリゴヌクレオチド治療薬は、合成オリゴヌクレオチド（DNAまたはRNAの短い鎖）を用いて、細胞内の遺伝子発現やタンパク質機能を調節する、急速に台頭しつつある薬剤クラス別です。これらの治療薬は、特定の遺伝子を沈黙させ、修復し、あるいは発現を変化させるように設計されており、従来の低分子医薬品と比較して高度に標的化されています。オリゴヌクレオチド治療薬には、アンチセンス・オリゴヌクレオチド（ASO）、低分子干渉RNA（siRNA）、アプタマーなどが含まれ、遺伝性疾患、がん、心血管疾患など様々な疾患の治療に使用されています。分子レベルで疾患に対処するこれらの能力は、精密医療における重要な進歩であり、これまで治療不可能であった疾患に新たな希望を与えるものです。遺伝性疾患や希少疾患の調査が進むにつれ、情勢は製薬業界にとって重要な要素になりつつあり、科学界と製薬会社の双方から大きな関心が寄せられています。

技術革新はどのようにオリゴヌクレオチド治療薬の限界を押し広げているのでしょうか？

オリゴヌクレオチドの化学、送達システム、製造プロセスにおける技術的進歩は、オリゴヌクレオチド治療薬の成功に極めて重要な役割を果たしています。オリゴヌクレオチドの安定性と生物学的利用能を向上させるホスホロチオエートバックボーンや脂質ナノ粒子デリバリーシステムなどの改良により、血流中での不安定性や特定の組織を標的にすることの難しさといった初期の限界に対処してきました。さらに、RNA干渉（RNAi）やCRISPRのような遺伝子編集技術の革新は、オリゴヌクレオチドに基づく治療の範囲を大幅に拡大しました。人工知能（AI）や計算生物学の進歩も、より効果的で正確なオリゴヌクレオチドの設計を助け、オフターゲット効果を減らし、治療効果を向上させています。さらに、ハイスループット合成技術の開発により、大量のオリゴヌクレオチド・ライブラリーの迅速な生産が可能になり、創薬・開発プロセスが加速されています。このような技術的飛躍的進歩により、オリゴヌクレオチド治療薬に関連する従来の課題が克服され、主流となる臨床使用がますます現実味を帯びてきています。

オリゴヌクレオチド治療薬はどのような疾患をターゲットにしており、なぜ需要が伸びているのか？

オリゴヌクレオチドの治療可能性の拡大により、オリゴヌクレオチドは広範な遺伝性疾患や希少疾患に対処するための重要なソリューションとして位置づけられています。オリゴヌクレオチド治療薬は、欠陥遺伝子をサイレンシングまたは修正することにより、疾患の根本原因をターゲットにすることができます。Spinraza（脊髄性筋萎縮症治療薬）やTegsedi（遺伝性トランスサイレチン介在性アミロイドーシス治療薬）のような承認された治療薬は、神経筋疾患、腫瘍学、代謝性疾患へのさらなる研究の舞台を整えました。腫瘍学では、オリゴヌクレオチド治療薬は、がん遺伝子を阻害したり、がん抑制遺伝子の発現を増強したりする能力について研究されており、がん治療の新たな道を切り開いています。さらに、心血管系疾患、眼疾患、ウイルス感染においても有望視されています。これらの治療法は、個々の患者の遺伝子構成に基づいたオーダーメイドの治療選択肢を提供するという個別化された性質が需要を牽引しており、この傾向は精密医療に向けた広範な動きと一致しています。

オリゴヌクレオチド治療薬市場の成長を促進する主な要因は？

オリゴヌクレオチド治療薬市場の成長は、主に承認された治療法の増加や治療用途の拡大など、いくつかの要因によってもたらされます。RNA干渉やアンチセンス・オリゴヌクレオチドなどのRNA標的化技術の進歩により、アンメット・メディカル・ニーズの高い疾患の治療に新たな扉が開かれました。精密医療への注目の高まりや希少遺伝性疾患の治療法の開発も、従来の治療法では不可能な、標的を絞った個別化された解決策を提供することから、大きな成長促進要因となっています。さらに、がん、心血管系疾患、その他の慢性疾患に対する継続的な研究が、オリゴヌクレオチドをベースとした治療法の需要を押し上げています。脂質ナノ粒子やエクソンスキッピング技術など、ドラッグデリバリー方法の技術的進歩は、これらの薬剤の有効性と安全性プロファイルをさらに向上させています。バイオテクノロジーへの投資の増加や、医薬品承認の迅速化に対する規制当局の支援も、市場の拡大に寄与しています。製薬企業がオリゴヌクレオチドの研究開発に投資を続けていることから、市場は今後数年間で力強い成長を遂げることが予想されます。

調査対象企業の例（注目の44社）

  • Alnylam Pharmaceuticals, Inc.
  • AnaBioTec NV
  • Arrowhead Pharmaceuticals, Inc.
  • Avidity Biosciences
  • Axispharm Laboratories Ltd.
  • Axolabs
  • Bachem AG
  • baseclick GmbH
  • Bio Basic Inc.
  • Biogen, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP13701

Global Oligonucleotide Therapeutics Market to Reach US$4.9 Billion by 2030

The global market for Oligonucleotide Therapeutics estimated at US$2.8 Billion in the year 2023, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2023-2030. Antisense / RNAI Oligonucleotides Technology, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Other Technologies segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$762.6 Million While China is Forecast to Grow at 7.9% CAGR

The Oligonucleotide Therapeutics market in the U.S. is estimated at US$762.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$744.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Global Oligonucleotide Therapeutics Market – Key Trends & Drivers Summarized

What Are Oligonucleotide Therapeutics and Why Are They a Game Changer?

Oligonucleotide therapeutics are a rapidly emerging class of drugs that use synthetic oligonucleotides (short strands of DNA or RNA) to modulate gene expression or protein function within cells. These therapies are designed to silence, repair, or alter the expression of specific genes, making them highly targeted compared to traditional small-molecule drugs. Oligonucleotide therapeutics include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, which are being used to treat a range of diseases, including genetic disorders, cancers, and cardiovascular conditions. Their ability to address diseases at the molecular level represents a significant advancement in precision medicine, offering new hope for previously untreatable conditions. As research into genetic and rare diseases progresses, oligonucleotide therapeutics are becoming a vital component of the pharmaceutical landscape, driving significant interest from both the scientific community and pharmaceutical companies.

How Are Technological Innovations Pushing the Boundaries of Oligonucleotide Therapeutics?

Technological advancements in oligonucleotide chemistry, delivery systems, and manufacturing processes are playing a pivotal role in the success of oligonucleotide therapeutics. Early limitations, such as instability in the bloodstream and difficulties in targeting specific tissues, have been addressed through modifications like phosphorothioate backbones and lipid nanoparticle delivery systems, which enhance the stability and bioavailability of oligonucleotides. Furthermore, innovations in RNA interference (RNAi) and gene editing technologies, such as CRISPR, have significantly expanded the scope of oligonucleotide-based therapies. Advances in artificial intelligence (AI) and computational biology are also aiding in the design of more effective and precise oligonucleotides, reducing off-target effects and improving therapeutic efficacy. Additionally, the development of high-throughput synthesis technologies allows for the rapid production of large libraries of oligonucleotides, accelerating drug discovery and development processes. These technological breakthroughs are helping to overcome the traditional challenges associated with oligonucleotide therapeutics, making them increasingly viable for mainstream clinical use.

What Diseases Are Oligonucleotide Therapeutics Targeting and Why Is Demand Growing?

The expanding therapeutic potential of oligonucleotides has positioned them as a key solution for addressing a wide range of genetic and rare diseases. One of the primary areas of focus is rare genetic disorders, where oligonucleotide therapeutics can target the root cause of the disease by silencing or modifying defective genes. Approved treatments like Spinraza (for spinal muscular atrophy) and Tegsedi (for hereditary transthyretin-mediated amyloidosis) have set the stage for further exploration into neuromuscular diseases, oncology, and metabolic conditions. In oncology, oligonucleotide therapeutics are being explored for their ability to inhibit oncogenes or enhance the expression of tumor suppressor genes, creating novel avenues for cancer treatment. Additionally, they are showing promise in cardiovascular diseases, ocular disorders, and viral infections. The personalized nature of these therapies is driving demand, as they offer tailored treatment options based on the genetic makeup of individual patients, a trend that aligns with the broader move toward precision medicine.

What Are the Key Drivers Fueling Growth in the Oligonucleotide Therapeutics Market?

The growth in the oligonucleotide therapeutics market is driven by several factors, primarily the increasing number of approved therapies and their expanding therapeutic applications. Advances in RNA-targeting technologies, such as RNA interference and antisense oligonucleotides, have opened new doors for treating diseases with high unmet medical needs. The growing focus on precision medicine and the development of treatments for rare genetic disorders are also significant growth drivers, as these therapies offer targeted, personalized solutions that conventional treatments cannot provide. Additionally, ongoing research into cancer, cardiovascular diseases, and other chronic conditions is pushing the demand for oligonucleotide-based therapies. Technological advancements in delivery methods, such as lipid nanoparticles and exon-skipping technologies, are further improving the effectiveness and safety profiles of these drugs. Increased investment in biotechnology, along with regulatory support for accelerated drug approvals, is also contributing to the market’s expansion. As pharmaceutical companies continue to invest in oligonucleotide research and development, the market is expected to see robust growth in the coming years.

Select Competitors (Total 44 Featured) -

  • Alnylam Pharmaceuticals, Inc.
  • AnaBioTec NV
  • Arrowhead Pharmaceuticals, Inc.
  • Avidity Biosciences
  • Axispharm Laboratories Ltd.
  • Axolabs
  • Bachem AG
  • baseclick GmbH
  • Bio Basic Inc.
  • Biogen, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Oligonucleotide Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Genetic Disorders and Rare Diseases Drives Adoption of Oligonucleotide-Based Therapeutics in Precision Medicine
    • Growing Investment in Antisense Oligonucleotides and RNA Interference Therapies Propels Growth in the Oligonucleotide Therapeutics Market
    • Advancements in RNA-Based Therapeutics, Including siRNA and mRNA, Strengthen the Business Case for Expanding Oligonucleotide Drug Development Pipelines
    • Increasing Focus on Gene Silencing and Exon Skipping Techniques Using Oligonucleotides Spurs Market Growth in Neurological Disorders
    • Rise of CRISPR and Gene Editing Technologies Expands the Addressable Market Opportunity for Oligonucleotide Therapeutics
    • Improved Oligonucleotide Delivery Systems, Including Lipid Nanoparticles and Conjugation Technologies, Drive the Efficacy of Therapeutic Applications
    • FDA Approvals of Key Oligonucleotide-Based Drugs Accelerate Market Growth and Boost Investor Confidence in Therapeutic Development
    • Growing Application of Oligonucleotides in Oncology, Including Targeted Cancer Therapies, Generates Demand for Advanced Therapeutics
    • Increasing Collaborations Between Pharma and Biotech Companies and Oligonucleotide Specialists Boost Therapeutic Innovation
    • Technological Advancements in Nucleic Acid Synthesis and Modifications Propel the Development of Next-Generation Oligonucleotide Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oligonucleotide Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antisense / RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antisense / RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antisense / RNAI Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Oligonucleotide Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Oligonucleotide Therapeutics by Technology - Antisense / RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense / RNAI Oligonucleotides and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION